SCHEMBL18368366

SCHEMBL18368366

Cc1nc2cccc(C(C)C)c2s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
TLR8 Q9NR97 2/20 0.39
TLR7 Q9NYK1 2/20 0.39
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
FAAH O00519 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
GABRB1 P18505 1/20 0.38
PTGS1 P23219 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2C P28335 1/20 0.38
GABRA5 P31644 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19224384 0.81 TLR8 (0.46) RAB9ATLR8TLR7LMNAHPGD
SCHEMBL18905196 0.80 SMN1; SMN2 (0.44) RAB9ANPC1TLR8TLR7LMNA
SCHEMBL13511828 0.79 LOXL2 (0.37) RAB9ANPC1TLR8TLR7SMN1; SMN2
SCHEMBL31063715 0.76 RAB9A (0.49) RAB9ANPC1TLR8TLR7LMNA
SCHEMBL7958840 0.76 RAB9A (0.49) RAB9ANPC1TLR8TLR7LMNA
SCHEMBL24256511 0.76 PSMB8 (0.59) LMNAHPGDGABRA1GABRG2GABRB3
SCHEMBL17050426 0.75 RAB9A (0.41) RAB9ANPC1TLR8TLR7LMNA
SCHEMBL20049220 0.75 RAB9A (0.41) RAB9ANPC1TLR8TLR7HPGD
SCHEMBL4857995 0.75 APP (0.50) RAB9ANPC1TLR8TLR7HPGD
SCHEMBL7216764 0.73 RAB9A (0.42) RAB9ANPC1TLR8TLR7LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
US-11827662-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2023-11-28 US disclosed
US-20230331717-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-10-19 US disclosed
US-20230219947-A1 INHIBITORS OF AV ß6 INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-07-13 US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 US disclosed
US-20230002407-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2023-01-05 US disclosed
US-11325930-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2022-05-10 US disclosed
US-11066414-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2021-07-20 US disclosed
US-20210147454-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2021-05-20 US disclosed
US-20200123172-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2020-04-23 US disclosed
US-9878995-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-01-30 US disclosed
US-9878995-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-01-30 US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 US disclosed
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325930-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885
US-20230219947-A1 INHIBITORS OF AV ß6 INTEGRIN ITGB6, ITGA6, GP6 RAB9A 1046/4885NPC1 1205/4885TLR8 3708/4885
US-20230331717-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TP53, KRAS, HRAS RAB9A 1020/4885NPC1 2176/4885TLR8 3441/4885
US-20230002407-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885
US-20200123172-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TP53, HRAS, KRAS RAB9A 1212/4885NPC1 2050/4885TLR8 4060/4885
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885
US-11066414-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB RAB9A 2053/4885NPC1 1287/4885TLR8 4231/4885
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885
US-20210147454-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885
US-11827662-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS RAB9A 4028/4885NPC1 4279/4885TLR8 3778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.